Serological markers and long COVID —A rapid systematic review
European Journal of Clinical Investigation · 2024
DOI: 10.1111/eci.14149 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Clinical Investigation, 2024. Verfasst von Erin Collins und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: COVID-19, Immunoglobulin G, Biomarkers, SARS-CoV-2. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Background
Long COVID is highly heterogeneous, often debilitating, and may last for years after infection. The aetiology of long COVID remains uncertain. Examination of potential serological markers of long COVID, accounting for clinical covariates, may yield emergent pathophysiological insights.
Methods
In adherence to PRISMA guidelines, we carried out a rapid review of the literature. We searched Medline and Embase for primary observational studies that compared IgG response in individuals who experienced COVID‐19 symptoms persisting ≥12 weeks post‐infection with those who did not. We examined relationships between serological markers and long COVID status and investigated sources of inter‐study variability, such as severity of acute illness, long COVID symptoms assessed and target antigen(s).
Results
Of 8018 unique records, we identified 29 as being eligible for inclusion in synthesis. Definitions of long COVID varied. In studies that reported anti‐nucleocapsid (N) IgG ( n = 10 studies; n = 989 participants in aggregate), full or partial anti‐Spike IgG (i.e. the whole trimer, S1 or S2 subgroups, or receptor binding domain, n = 19 studies; n = 2606 participants), or neutralizing response ( n = 7 studies; n = 1123 participants), we did not find strong evidence to support any difference in serological markers between groups with and without persisting symptoms. However, most studies did not account for severity or level of care required during acute illness, and other potential confounders.
Conclusions
Pooling of studies would enable more robust exploration of clinical and serological predictors among diverse populations. However, substantial inter‐study variations hamper comparability. Standardized reporting practices would improve the quality, consistency and comprehension of study findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
- Department of Mathematics and Statistics, University of Ottawa, Ottawa, Ontario, Canada.
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
- Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
- Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.
- Coronavirus Variants Rapid Response Network (CoVaRR-Net), Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
ORCID-Profile: Erin Collins
Förderung
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Collins, E., Philippe, E., Gravel, C. A., Hawken, S., Langlois, M. A., & Little, J. (2024). Serological markers and long COVID —A rapid systematic review. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14149
Vancouver
Collins E, Philippe E, Gravel CA, Hawken S, Langlois MA, Little J. Serological markers and long COVID —A rapid systematic review. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14149
BibTeX
@article{Collins2024,
author = {Collins, Erin and Philippe, Elizabeth and Gravel, Christopher A and Hawken, Steven and Langlois, Marc-André and Little, Julian},
title = {Serological markers and long COVID —A rapid systematic review},
journal = {European Journal of Clinical Investigation},
year = {2024},
doi = {10.1111/eci.14149}
}
EUVIMED